Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study
Background Statins are hypothesized to reduce the risk of cardiotoxicity associated with anthracyclines and trastuzumab. Our aim was to study the association of statin exposure with hospitalization or emergency department visits (hospital presentations) for heart failure (HF) after anthracycline‐ an...
Main Authors: | Husam Abdel‐Qadir, David Bobrowski, Limei Zhou, Peter C. Austin, Oscar Calvillo‐Argüelles, Eitan Amir, Douglas S. Lee, Paaladinesh Thavendiranathan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.119.018393 |
Similar Items
-
Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer
by: Sivisan Suntheralingam, et al.
Published: (2022-02-01) -
Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters
by: Belén Díaz‐Antón, et al.
Published: (2022-04-01) -
Cardiotoxicity: Importance of biomarkers
by: Kostadinović Jelena, et al.
Published: (2023-01-01) -
Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01) -
An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study
by: Jukapun Yoodee, et al.
Published: (2021-08-01)